Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

5

Revenue 2017

Avastin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avastin was produced by Roche.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer

category with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq plus Avastin to Sutent, which showed  positive effects on PFS at last year’s ASCO meeting.

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Chi-Med and Lilly’s cancer drug Elunate a milestone for China The VEGF-inhibitor class is already well-established outside China – in fact Roche’s Avastin is now available as a biosimilar in Europe – but it has never been approved in China,

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer combination of Tecentriq and Avastin may play a role in the treatment of metastatic RCC [which] remains an area of high unmet medical need.”. ... In that trial Tecentriq and Avastin were compared to chemotherapy in non-squamous NSCLC.

Roche’s new flu pill Xofluza approved in US

Roche’s new flu pill Xofluza approved in US Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

Keytruda hits survival targets in first-line kidney cancer

Keytruda hits survival targets in first-line kidney cancer with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin (bevacizumab) to Sutent, which showed positive effects on PFS at this year’s ASCO meeting.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics